{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-330541","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2026-08-03T20:05:21+00:00","discovered_at":"2026-08-03T20:08:08.476928+00:00","generated_at":"2026-08-03T20:09:58.511331+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ClearPoint Neuro Q2 revenue $10.9M (+18% YoY); revises 2026 guidance to $48-52M","bullets":["Q2 revenue $10.9M (+18% YoY); Biologics & Drug Delivery revenue fell 15% to $4.0M.","Neurosurgery navigation revenue surged 62% to $5.6M on IRRA flow and software.","Operating expenses rose 51% to $17.0M; cash at $29.4M, down from $45.9M at year-end.","2026 revenue guidance revised to $48-52M; company prioritizing clinical capacity and new tech.","Multiple biopharma partners received positive FDA feedback; expects 10-15 trials enrolling in 18 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-330541","json":"https://secwatch.observer/filing/0001193125-26-330541.json","markdown":"https://secwatch.observer/filing/0001193125-26-330541.md","text":"https://secwatch.observer/filing/0001193125-26-330541.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000119312526330541/0001193125-26-330541-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000119312526330541/clpt-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T20:09:58.511331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}